126 related articles for article (PubMed ID: 38847351)
1. Implementation of statistical features of a Bayesian two-armed responsive adaptive randomization trial with post hoc analysis of time trend drift.
Shergina E; Richter KP; Zhang C; Mussulman L; Nazir N; Gajewski BJ
J Biopharm Stat; 2024 Jun; ():1-15. PubMed ID: 38847351
[TBL] [Abstract][Full Text] [Related]
2. Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN.
Brown AR; Gajewski BJ; Mudaranthakam DP; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Mayo MS; Barohn RJ
Contemp Clin Trials Commun; 2023 Dec; 36():101220. PubMed ID: 37965484
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.
Gajewski BJ; Statland J; Barohn R
Stat Biopharm Res; 2019; 11(4):375-386. PubMed ID: 31839873
[TBL] [Abstract][Full Text] [Related]
5. Simulation study for evaluating the performance of response-adaptive randomization.
Du Y; Wang X; Jack Lee J
Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness Research using Bayesian Adaptive Designs for Rare Diseases: Response Adaptive Randomization Reusing Participants.
Tang F; Gajewski BJ
Stat Biopharm Res; 2023; 15(1):154-163. PubMed ID: 36875290
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
[TBL] [Abstract][Full Text] [Related]
8. The value of a two-armed Bayesian response adaptive randomization trial.
Gajewski BJ; Carlson SE; Brown AR; Mudaranthakam DP; Kerling EH; Valentine CJ
J Biopharm Stat; 2023 Jan; 33(1):43-52. PubMed ID: 36411742
[TBL] [Abstract][Full Text] [Related]
9. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
Meinzer C; Martin R; Suarez JI
Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
[TBL] [Abstract][Full Text] [Related]
10. Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?
Villar SS; Bowden J; Wason J
Pharm Stat; 2018 Mar; 17(2):182-197. PubMed ID: 29266692
[TBL] [Abstract][Full Text] [Related]
11. Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints.
Cao W; Zhu H; Wang L; Zhang L; Yu J
Stat Med; 2024 Apr; 43(9):1743-1758. PubMed ID: 38387866
[TBL] [Abstract][Full Text] [Related]
12. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
Ryan EG; Lamb SE; Williamson E; Gates S
Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
[TBL] [Abstract][Full Text] [Related]
13. Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.
Gao G; Gajewski BJ; Wick J; Beall J; Saver JL; Meinzer C;
Trials; 2022 Sep; 23(1):754. PubMed ID: 36068547
[TBL] [Abstract][Full Text] [Related]
14. Bayesian response adaptive randomization using longitudinal outcomes.
Hatayama T; Morita S; Sakamaki K
Pharm Stat; 2015; 14(5):369-76. PubMed ID: 26099995
[TBL] [Abstract][Full Text] [Related]
15. Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes.
Proper J; Connett J; Murray T
Clin Trials; 2021 Aug; 18(4):417-426. PubMed ID: 33926267
[TBL] [Abstract][Full Text] [Related]
16. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
Zhu H
J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
[TBL] [Abstract][Full Text] [Related]
17. Resist the Temptation of Response-Adaptive Randomization.
Proschan M; Evans S
Clin Infect Dis; 2020 Dec; 71(11):3002-3004. PubMed ID: 32222766
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
[TBL] [Abstract][Full Text] [Related]
19. Bayesian response adaptive randomization design with a composite endpoint of mortality and morbidity.
Xu Z; Ma T; Tang L; Talisa VB; Chang CH
Stat Med; 2024 Mar; 43(6):1256-1270. PubMed ID: 38258898
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Opt-out vs Opt-in Tobacco Treatment on Engagement, Cessation, and Costs: A Randomized Clinical Trial.
Richter KP; Catley D; Gajewski BJ; Faseru B; Shireman TI; Zhang C; Scheuermann TS; Mussulman LM; Nazir N; Hutcheson T; Shergina E; Ellerbeck EF
JAMA Intern Med; 2023 Apr; 183(4):331-339. PubMed ID: 36848129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
